Key facts
- It has raised $1.0M; the latest was Later Stage VC ($1.0M) in Aug 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for General Metabolics
- ·The full record, as it builds
Funding rounds
No funding rounds for General Metabolics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About General Metabolics
Developer and provider of research and reporting software designed to simplify metabolomics data management, organization, and visualization. The company's web-based tools organize the metabolomics and other data into informative and engaging interactive reports by creating an extensive collection of data organizing tools, including ontologies, pathway maps, annotations, and algorithms, enabling individuals, institutions, and researchers to find relationships between genes and metabolites to uncover novel biological mechanisms.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 7
- Website
- generalmetabolics.com/
- Ownership
- Privately Held (backing)
General Metabolics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in General Metabolics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on General Metabolics in its N-PORT filings yet. We sweep new filings monthly.